Stifel analysts maintained a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) with a steady price target of $21.00. According to InvestingPro data, the stock currently trades at $6.40, with analyst ...
The team of three advisors have started a firm called T6 Wealth Management, which will operate out of Morgan Stanley's new ...
Stifel Financial Corp (NYSE:SF). has announced a revision to its executive compensation structure, according to a recent SEC filing. On Monday, the Compensation Committee of the Board of Directors ...
Stifel Raises Quarterly Common Stock Cash Dividend by 10% and Declares Preferred Stock Cash Dividend
LOUIS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE ... The Company’s Series B Preferred Stock trades on the New York Stock Exchange under the symbol “SF PrB”, the Company’s Series C ...
NEW YORK, January 21, 2025--(BUSINESS WIRE)--Alpaca Real Estate ("ARE"), an alternative investment management firm, announced today the closing of a $50 million credit facility with Stifel Bank. This ...
Ron Kruszewski, Stifel's chairman and CEO, told financial analysts that its investment banking franchise is well-positioned ...
Research analysts at Stifel Canada issued their Q4 2024 earnings estimates for shares of Franco-Nevada in a research note ...
(RTTNews) - Stifel Financial Corp. (SF ... Inc. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback